Skip Navigation


Rheumatology Advance Access originally published online on May 22, 2006
Rheumatology 2006 45(8):935-936; doi:10.1093/rheumatology/kel145
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
45/8/935    most recent
kel145v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Walker, D. J.
Right arrow Articles by Moots, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walker, D. J.
Right arrow Articles by Moots, R. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

EDITORIAL

A patient-centred approach to drug regulation

D. J. Walker and R. J. Moots1

Freeman Hospital, Newcastle NE7 7DN and 1 Department of Rheumatology, University of Liverpool, University Hospital Aintree, Longmoor Lane, Liverpool L9 7AL, UK

Correspondence to: Dr Walker. E-mail: david.walker@nuth.nhs.uk

The first 150 words of the full text of this article appear below.

It would be naïve, indeed, to expect to be able to inhibit a biological system that exists because it has increased its chances of survival to procreation age and not expect to pay a biological price for it. Drugs, whose effects are mediated by such inhibition, will therefore inevitably have the potential for causing side effects, and the ‘perfect’ fully safe yet effective drug is yet to be produced. It is, therefore, of paramount importance to balance drug efficacy with safety—but of late it appears that patients' needs do not occupy the forefront of this important process, as they should.

The recent withdrawal of drugs such as rofecoxib [1], valdecoxib [2] and coproxamol [3], which were widely used to treat pain in arthritis, have led to many serious repercussions in the delivery of care to patients with arthritis. Many patients have been left in . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
P. Huston
A patient's perspective on drug regulation
Rheumatology, October 1, 2007; 46(10): 1618 - 1618.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
K. A. Binymin and K. Phillips
"To do no harm"
Rheumatology, February 1, 2007; 46(2): 368 - 370.
[Full Text] [PDF]